Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.

Vaccine

Michael G. DeGroote Institute for Infectious Disease Research, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Published: October 2010

AI Article Synopsis

Article Abstract

Induction of neutralizing antibodies to prevent HIV infection, especially at the mucosa, is a critical goal of future vaccines. In this study, we have designed chimeric HIV-gag virus-like particles (VLPs) that contain multiple copies of the two highly conserved gp41 membrane-proximal external region (MPER) epitopes, ELDKWA and NWFDIT, with the objective of generating high titers of MPER-specific antibodies. We have shown that the implementation of optimized vector design, delivery regimens and appropriate delivery methods is critical to significantly increase epitope-specific antibody titers. One goal of the methods that were tested and employed was to generate high levels of mucosal MPER-specific antibodies, as mucosal immune induction could play a key role in preventing HIV infection. We also tested a design strategy that incorporated multiple repeats of the MPER epitopes within gag, which significantly increased specific antibody titers, systemically and mucosally. This alternative design strategy and the implementation of optimized heterologous immunization regimens can serve to 'immuno-focus' and significantly increase epitope-specific titers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2010.08.009DOI Listing

Publication Analysis

Top Keywords

conserved gp41
8
virus-like particles
8
optimized heterologous
8
hiv infection
8
mper epitopes
8
mper-specific antibodies
8
implementation optimized
8
increase epitope-specific
8
antibody titers
8
design strategy
8

Similar Publications

Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.

Vaccine

December 2024

Mucosal Immunoogy Laboratory, Biomedicine Research Unit, Faculty of Higher Studies Iztacala, National Autonomous University of Mexico. Avenida de los Barrios 1, Los Reyes Iztacala, Tlalnepantla, Estado de México 54090, Mexico. Electronic address:

The development of a protective HIV vaccine remains a challenge given the high antigenic diversity and mutational rate of the virus, which leads to viral escape and establishment of reservoirs in the host. Modern antigen design can guide immune responses towards conserved sites, consensus sequences or normally subdominant epitopes, thus enabling the development of broadly neutralizing antibodies and polyfunctional lymphocyte responses. Conventional epitope vaccines can often be impaired by low immunogenicity, a limitation that may be overcome by using a carrier system.

View Article and Find Full Text PDF

, formerly , is a bacterial species characterized by tenacious acne-contributing pathogenic strains. Therefore, bacteriophage therapy has become an attractive treatment route to circumvent issues such as evolved bacterial antibiotic resistance. However, medical and commercial use of phage therapy for has been elusive, necessitating ongoing exploration of phage characteristics that confer bactericidal capacity.

View Article and Find Full Text PDF

The majority of naturally elicited antibodies against the HIV-1 envelope glycoproteins (Env) are non-neutralizing (nnAbs) because they are unable to recognize the Env trimer in its native "closed" conformation. Nevertheless, it has been shown that nnAbs have the potential to eliminate HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) provided that Env is present on the cell surface in its "open" conformation. This is because most nnAbs recognize epitopes that become accessible only after Env interaction with CD4 and the exposure of epitopes that are normally occluded in the closed trimer.

View Article and Find Full Text PDF

Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation.

Curr Res Microb Sci

July 2024

Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, China.

Article Synopsis
  • The hydrophobic pocket of HIV-1 gp41 NHR is essential for forming a six-helix bundle during viral fusion, making it a prime target for drug design.
  • However, the size of traditional antibodies like IgG prevents them from fitting into this pocket during the crucial fusion process.
  • Nanobodies (Nbs), specifically Nb-172, have been developed to target this region and show promising neutralizing effects against various HIV-1 strains, suggesting their potential as a therapeutic option.
View Article and Find Full Text PDF

ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41.

Curr Res Microb Sci

July 2024

Hebei Key Laboratory of Analysis and Control of Zoonotic Pathogenic Microorganism, College of Life Sciences, Hebei Agricultural University, Baoding, 071001, China.

Article Synopsis
  • HIV-1 envelope glycoprotein gp41 is crucial for the virus to fuse with host cells, making it a target for anti-HIV drugs.
  • A new compound named ADS-J21 has been developed, which shares a similar Y-shaped structure with the previously studied ADS-J1 but has a lower molecular weight and shows effective activity against various HIV-1 strains.
  • Research showed that ADS-J21 works by blocking the formation of a critical structure (the six-helix bundle) in gp41, paving the way for it to be optimized as a small-molecule fusion inhibitor.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!